Erratum: Corrigendum to “Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes” (Parkinsonism and Related Disorders (2015) 21(3) (231–235)(S1353802014004866)(10.1016/j.parkreldis.2014.12.012));Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes

Parkinsonism and Related Disorders

Volumn 21, Issue 3, 2015, Pages 231-235

  Antonini, Angelo ^a   Yegin, Ashley ^b   Preda, Cornelia ^b   Bergmann, Lars ^b   Poewe, Werner ^c  

^a IRCCS SAN CAMILLO HOSPITAL   (Italy)

^b ABBVIE INC   (United States)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Advanced Parkinson's disease; Duodenal levodopa carbidopa infusion; Motor symptoms; Non motor symptoms; Quality of life; Routine patient care

Indexed keywords

CARBIDOPA PLUS LEVODOPA; ANTIPARKINSON AGENT; CARBIDOPA; GEL; LEVODOPA;

ABDOMINAL PAIN; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEVICE DISLOCATION; DEVICE SAFETY; DRUG DELIVERY DEVICE; DUODENUM ULCER; DYSKINESIA; EQ 5D SCORE; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL STOMA COMPLICATION; GRANULOMA; HALLUCINATION; HEART FAILURE; HEART INFARCTION; HUMAN; INFUSION PUMP; INJECTION SITE INFECTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; NAUSEA; NEUROLOGIC EXAMINATION; NON MOTOR SYMPTOMS SCALE; OBSERVATIONAL STUDY; PARKINSON DISEASE; PDQ 8 SCORE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; POLYNEUROPATHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; QUALITY OF LIFE; SURGICAL INFECTION; UNIFIED PARKINSON DISEASE RATING SCALE; WEIGHT REDUCTION; CLINICAL TRIAL; EUROPE; GEL; INTERNATIONAL COOPERATION; INTESTINE; LONGITUDINAL STUDY; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEVERITY OF ILLNESS INDEX; THERAPEUTIC USE; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; CARBIDOPA; EUROPE; FEMALE; GELS; HUMANS; INTERNATIONAL COOPERATION; INTESTINES; LEVODOPA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84923230653     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2016.08.012     Document Type: Erratum

References (30)

1. Wirdefeldt K., Adami H.O., Cole P., Trichopoulos D., Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011, 26:S1-S58.
2. NHS clinical knowledge summaries. http://cks.library.nhs.uk/parkinsons_disease/management/quick_answers/scenario_ongoing_management#-245373.
3. Chapuis S., Ouchchane L., Metz O., Gerbaud L., Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005, 20:224-230.
4. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz C.G. Levodopa induced dyskinesias. Mov Disord 2007, 22:1379-1389.
5. Chaudhuri K.R., Martinez-Martin P., Brown R.G., et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. Mov Disord 2007, 22:1901-1911.
6. Schapira A.H. Treatment options in the modern management of Parkinson disease. Arch Neurol 2007, 64:1083-1088.
7. Nyholm D., Nilsson Remahl A.I., Dizdar N., Constantinescu R., Holmberg B., Jansson R., et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurol 2005, 64:216-223.
8. Olanow C.W., Kieburtz K., Odin P., Espay A.J., Standaert D.G., Fernandez H.H., et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol 2013, 13:141-149. for the LCIG Horizon Study Group.
9. Kurth M.C., Tetrud J.W., Tanner C.M., et al. Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. Neurol 1993, 43:1698-1703.
10. Antonini A., Bondiolotti G., Natuzzi F., Bareggi S.R. Levodopa and 3-OMD levels in Parkinson subjects treated with duodopa. Eur Neuropsychopharmacol 2010, 20:683-687.
11. Fernandez H.H., Vanagunas A., Odin P., Espay A.J., Hauser R.A., Standaert D.G., et al. Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results. Parkinsonism Relat Disord 2013, 19:339-345.
12. Chaudhuri K.R., Rizos A., Sethi K.D. Motor and non-motor complications in Parkinson's disease: an argument for continuous drug delivery?. JNeural Transm 2013, 120:1305-1320.
13. Nyholm D., Lewander T., Johansson A., LeWitt P., Lundqvist C., Aquilonius S.-M. Long-term assessment of safety in patients treated with duodopa. Clin Neuropharmacol 2008, 31:63-73.
14. Zibetti M., Merola A., Ricchi V., Marchisio A., Artusi C.A., Rizzi L., et al. Long-term duodenal levodopa infusion in Parkinson's disease: a 3-year motor and cognitive follow-up study. JNeurol 2013, 260:105-114.
15. Pålhagen S.E., Dizdar N., Hauge T., Holmberg B., Jansson R., Linder J., et al. Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease. Acta Neurol Scand 2012, 126:29-33.
16. Antonini A., Mancini F., Canesi M., Zangaglia R., Isaias I.U., Manfredi L., et al. Assessment of the effectiveness of duodenal levodopa infusion on quality of life and motor features in patients with advanced Parkinson's disease. Neurodegener Disord 2008, 5:244-266.
17. Eggert K., Schrader C., Hahn M., et al. Continuous jejunal levodopa infusion in patients with advanced Parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008, 31:151-166.
18. Annic A., Devos D., Seguy D., Dujardin K., Destée A., Defebvre L. Assessment of efficacy and safety in duodenal levodopa infusion in advanced Parkinson's disease. Rev Neurol 2009, 165:718-727.
19. Antonini A., Mancini F., Canesi M. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neurodegener Disord 2008, 5:244-246.
20. Antonini A., Calandrella D., Mancini F., Odin P., Lopiano L., Zibetti M., et al. Duodenal levodopa infusion improves motor symptoms and quality of life in patients with advanced Parkinson's diseases: an outcome assessment in patient routine care. JNeural Transm 2012, 120:1553-1558.
21. Foltynie T., Magee C., James C., Webster G.J., Lees A.J., Limousin P. Impact of duodopa on quality of life in advanced Parkinson's disease: a UK case series. Park Dis 2013, e362908.
22. Goetz C.G.1, Tilley B.C., Shaftman S.R., Stebbins G.T., Fahn S., Martinez-Martin P., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008, 15(23):2129-2170. Movement Disorder Society UPDRS Revision Task Force.
23. Antonini A., Albin R.L. Dopaminergic treatment and non-motor features of Parkinson disease. Neurol 2013, 80:784-785.
24. Storch A., Schneider C.B., Wolz M., Stürwald Y., Nebe A., Odin P., et al. Nonmotor fluctuations in Parkinson disease: severity and correlation with motor complications. Neurol 2013, 26(80):800-809.
25. Tinazzi M., Abbruzzese G., Antonini A., Ceravolo R., Fabbrini G., Lessi P., et al. Reasons driving treatment modification in Parkinson's disease: results from the cross-sectional phase of the REASON study. Parkinsonism Relat Disord 2013, 19:1130-1135. REASON Study Group.
26. Merola A., Zibetti M., Rizzone M.G., Troiano M., Artusi C.A., Angrisano S., et al. Prospective assessment of peripheral neuropathy in duodopa-treated parkinsonian patients. Acta Neurol Scand 2013, 9:1-5.
27. Jugel C., Ehlen F., Taskin B., Marzinzik F., Müller T., Klostermann F. Neuropathy in Parkinson's disease patients with intestinal levodopa infusion versus oral drugs. PLoS One 2013;20, 8(6):e66639.
28. Müller T., van Laar T., Cornblath D.R., Odin P., Klostermann F., Grandas F.J., et al. Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. Parkinsonism Relat Disord 2013, 19:501-507.
29. Urban P.P., Wellach I., Faiss S., Layer P., Rosenkranz T., Knop K., et al. Subacute axonal neuropathy in Parkinson's disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord 2010, 25:1748-1752.
30. Mancini F., Comi C., Oggioni G.D., Pacchetti C., Calandrella D., Coletti Moja M., et al. Prevalence and features of peripheral neuropathy in Parkinson's disease patients under different therapeutic regimens. Parkinsonism Relat Disord 2014, 20:27-31.